438207-92-2

Upstream product

• 3332-29-4 O-ethylhydroxylamine hydrochloride 
• 305794-45-0 4-(4-bromobenzoyl)-1'-(tert-butoxycarbonyl)-4'-methyl-1,4'-bipiperidine 
• 498-94-2 isonipecotic acid 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 305794-42-7 4-[2-(4-bromophenyl)-1,3-dioxolan-2-yl]-1'-(tert-butoxycarbonyl)-4'-cyano-1,4'-bipiperidine 
• 305794-43-8 4-[2-(4-bromophenyl)-1,3-dioxolan-2-yl]-1'-(tert-butoxycarbonyl)-4'-methyl-1,4'-bipiperidine 
• 305794-44-9 (4-bromo-phenyl)-(4'-methyl-[1,4']bipiperidinyl-4-yl)-methanone 
• 203186-01-0 1-[4-(4-bromobenzoyl)piperidin-1-yl]-2,2,2-trifluoroethanone 
• 203186-02-1 4-[2-(4-bromophenyl)-1,3-dioxolan-2-yl]-piperidine 
• 126501-71-1 1-(2,2,2-trifluoroacetyl)piperidine-4-carbonyl chloride 

Downstream Products

• 370893-06-4 ancriviroc 
• 515881-16-0 4-[(Z)-(4-bromophenyl)(ethoxyimino)methyl]-1-(4-methyl-4-piperidinyl)-piperidine 
• 438207-93-3 4-[(4-bromo-phenyl)-ethoxyimino-methyl]-4'-methyl-[1,4']bipiperidinyl-1'-carboxylic acid tert-butyl ester 
• 816448-92-7 4-[(E)-(4-bromophenyl)(ethoxyimino)methyl]-1-(4-methyl-4-piperidinyl)piperidine 

Relevant academic research and scientific papers

QUINOLYL AMIDE DERIVATIVES AS CCR-5 ANTAGONISTS

The present invention relates to a series of compounds which are CCR-5 receptor antagonists of the general formula (I): or a pharmaceutically acceptable salt thereof, wherein the variables are defined herein.

Synthesis, SAR, and biological evaluation of oximino-piperidino-piperidine amides. 1. Orally bioavailable CCR5 receptor antagonists with potent anti-HIV activity

We previously reported the discovery of 4-[(Z)-(4-bromophenyl)(ethoxyimino)methyl]-1′-[(2,4-dimethyl-3 -pyridinyl)carbonyl]-4′-methyl-1,4′-bipipefidine N-oxide 1 (SCH 351125) as an orally bioavailable human CCR5 antagonist for the treatment of HIV-1 infec

Discovery of 4-[(Z)-(4-bromophenyl)(ethoxyimino)methyl]-1′-[(2,4-dimethyl- 3pyridinyl)carbonyl]-4′-methyl-1,4′bipiperidine N-oxide (SCH 351125): An orally bioavailable human CCR5 antagonist for the treatment of HIV infection

Structure - activity studies on piperidino-piperidine 3 led to the discovery of SCH 351125 (1), a selective CCR5 antagonist with potent activity against RANTES binding (Ki=2 nM), which possesses subnanomolar activity in blocking viral entry and